🇺🇸 Candesartan/HCT in United States
110 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 110
Most-reported reactions
- Acute Kidney Injury — 18 reports (16.36%)
- Hypotension — 14 reports (12.73%)
- Drug Interaction — 12 reports (10.91%)
- Nausea — 12 reports (10.91%)
- Off Label Use — 12 reports (10.91%)
- Hyponatraemia — 9 reports (8.18%)
- Vomiting — 9 reports (8.18%)
- Dizziness — 8 reports (7.27%)
- Fatigue — 8 reports (7.27%)
- Inflammation — 8 reports (7.27%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Candesartan/HCT approved in United States?
Candesartan/HCT does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Candesartan/HCT in United States?
Population Health Research Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.